Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Journey Medical Corporation (DERM : NSDQ)

• Company Description    Journey Medical Corporation is a commercial-stage pharmaceutical company. It focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Journey Medical Corporation is based in Scottsdale, Arizona. Number of Employees: 58

• Price / Volume Information    Yesterday's Closing Price: $6.19 Daily Weekly Monthly 20 Day Moving Average: 261,320 shares Shares Outstanding: 27.53 (millions) Market Capitalization: $170.44 (millions) Beta: 1.07 52 Week High: $9.56 52 Week Low: $4.31 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.48% -1.21% 12 Week 20.19% 16.90% Year To Date -19.71% -21.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9237 E VIA DE VENTURA BLVD. SUITE 105 - SCOTTSDALE,AZ 85258 USA ph: 480-434-6670 fax: - ir@jmcderm.com http://www.jmcderm.com

• General Corporate Information    Officers Claude Maraoui - Chief Executive Officer; President and Director Lindsay A. Rosenwald - Executive Chairman Joseph Benesch - Chief Financial Officer Neil Herskowitz - Director Justin Smith - Director Peer Information Journey Medical Corporation (GSAC) Journey Medical Corporation (CASIF) Journey Medical Corporation (ALCD.) Journey Medical Corporation (OMNN) Journey Medical Corporation (CGPI.) Journey Medical Corporation (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 48115J109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 27.53 Most Recent Split Date: (:1) Beta: 1.07 Market Capitalization: $170.44 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.17 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: 35.37 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.49 Price/Cash Flow: - Price / Sales: 2.64 EPS Growth vs. Year Ago Period: 55.56% vs. Previous Quarter: -100.00% Sales Growth vs. Year Ago Period: 21.48% vs. Previous Quarter: -0.73% ROE 06/30/26 - - 03/31/26 - -35.57 12/31/25 - -46.40 ROA 06/30/26 - - 03/31/26 - -10.88 12/31/25 - -13.22 Current Ratio 06/30/26 - - 03/31/26 - 1.72 12/31/25 - 1.79 Quick Ratio 06/30/26 - - 03/31/26 - 1.47 12/31/25 - 1.53 Operating Margin 06/30/26 - - 03/31/26 - -14.82 12/31/25 - -18.48 Net Margin 06/30/26 - - 03/31/26 - -14.82 12/31/25 - -18.48 Pre-Tax Margin 06/30/26 - - 03/31/26 - -14.73 12/31/25 - -18.38 Book Value 06/30/26 - - 03/31/26 - 1.13 12/31/25 - 0.96 Inventory Turnover 06/30/26 - - 03/31/26 - 2.05 12/31/25 - 1.79 Debt-to-Equity 06/30/26 - - 03/31/26 - 0.74 12/31/25 - 0.79 Debt-to-Capital 06/30/26 - - 03/31/26 - 42.59 12/31/25 - 44.24

Powered by Zacks Investment Research ©